Product Code: TMRGL85111
The report provides revenue of the global smart drug delivery systems market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global smart drug delivery systems market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the smart drug delivery systems market.
The report delves into the competitive landscape of the global smart drug delivery systems market. Key players operating in the global smart drug delivery systems market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global smart drug delivery systems market profiled in this report.
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Smart Drug Delivery Systems Market
4. Market Overview
- 4.1. Overview
- 4.2. Market Dynamics
- 4.2.1. Drivers
- 4.2.2. Restraints
- 4.2.3. Opportunities
5. Key Insights
- 5.1. Smart Insulin Pen - Brand Analysis
- 5.2. Insulin Pen Delivery Devices Available in the U.S.
- 5.3. Insights on Digitization of Diabetes: Opportunities & Challenges
- 5.4. Key Industry Events (Partnership, Merger & Acquisition, etc.)
- 5.5. COVID-19 Impact Analysis
6. Global Smart Drug Delivery Systems Market Analysis and Forecast, by Product
- 6.1. Introduction & Definition
- 6.2. Key Findings/Developments
- 6.3. Market Value Forecast, by Product, 2017-2031
- 6.3.1. Connected Inhalers
- 6.3.2. Connected Autoinjectors
- 6.3.3. Connected Pen Injectors
- 6.3.4. Connected Wearable Injectors
- 6.3.5. Add-on Sensors
- 6.3.6. Others
- 6.4. Market Attractiveness Analysis, by Product
7. Global Smart Drug Delivery Systems Market Analysis and Forecast, by Drug Delivery Mode
- 7.1. Introduction & Definition
- 7.2. Key Findings/Developments
- 7.3. Market Value Forecast, by Drug Delivery Mode, 2017-2031
- 7.3.1. Injectable
- 7.3.2. Inhalation
- 7.3.3. Oral
- 7.4. Market Attractiveness Analysis, by Drug Delivery Mode
8. Global Smart Drug Delivery Systems Market Analysis and Forecast, by Therapeutic Area
- 8.1. Introduction & Definition
- 8.2. Key Findings/Developments
- 8.3. Market Value Forecast, by Therapeutic Area, 2017-2031
- 8.3.1. Metabolic Disorders
- 8.3.2. Neurological Disorders
- 8.3.3. Respiratory Disorders
- 8.3.4. Hormonal Disorders
- 8.3.5. Others
- 8.4. Market Attractiveness Analysis, by Therapeutic Area
9. Global Smart Drug Delivery Systems Market Analysis and Forecast, by End-user
- 9.1. Introduction & Definition
- 9.2. Key Findings/Developments
- 9.3. Market Value Forecast, by End-user, 2017-2031
- 9.3.1. Hospitals
- 9.3.2. Clinics
- 9.3.3. Home Care
- 9.3.4. Ambulatory Care Settings
- 9.3.5. Others
- 9.4. Market Attractiveness Analysis, by End-user
10. Global Smart Drug Delivery Systems Market Analysis and Forecast, by Region
- 10.1. Key Findings
- 10.2. Market Value Forecast, by Region, 2017-2031
- 10.2.1. North America
- 10.2.2. Europe
- 10.2.3. Asia Pacific
- 10.2.4. Latin America
- 10.2.5. Middle East & Africa
- 10.3. Market Attractiveness By Country/Region
11. North America Smart Drug Delivery Systems Market Analysis and Forecast
- 11.1. Introduction
- 11.2. Market Value Forecast, by Product, 2017-2031
- 11.2.1. Connected Inhalers
- 11.2.2. Connected Autoinjectors
- 11.2.3. Connected Pen Injectors
- 11.2.4. Connected Wearable Injectors
- 11.2.5. Add-on Sensors
- 11.2.6. Others
- 11.3. Market Value Forecast, by Drug Delivery Mode, 2017-2031
- 11.3.1. Injectable
- 11.3.2. Inhalation
- 11.3.3. Oral
- 11.4. Market Value Forecast, by Therapeutic Area, 2017-2031
- 11.4.1. Metabolic Disorders
- 11.4.2. Neurological Disorders
- 11.4.3. Respiratory Disorders
- 11.4.4. Hormonal Disorders
- 11.4.5. Others
- 11.5. Market Value Forecast, by End-user, 2017-2031
- 11.5.1. Hospitals
- 11.5.2. Clinics
- 11.5.3. Home Care
- 11.5.4. Ambulatory Care Settings
- 11.5.5. Others
- 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.6.1. U.S.
- 11.6.2. Canada
- 11.7. Market Attractiveness Analysis
- 11.7.1. By Product
- 11.7.2. By Drug Delivery Mode
- 11.7.3. By Therapeutic Area
- 11.7.4. By End-user
- 11.7.5. By Country/Sub-region
12. Europe Smart Drug Delivery Systems Market Analysis and Forecast
- 12.1. Introduction
- 12.2. Market Value Forecast, by Product, 2017-2031
- 12.2.1. Connected Inhalers
- 12.2.2. Connected Autoinjectors
- 12.2.3. Connected Pen Injectors
- 12.2.4. Connected Wearable Injectors
- 12.2.5. Add-on Sensors
- 12.2.6. Others
- 12.3. Market Value Forecast, by Drug Delivery Mode, 2017-2031
- 12.3.1. Injectable
- 12.3.2. Inhalation
- 12.3.3. Oral
- 12.4. Market Value Forecast, by Therapeutic Area, 2017-2031
- 12.4.1. Metabolic Disorders
- 12.4.2. Neurological Disorders
- 12.4.3. Respiratory Disorders
- 12.4.4. Hormonal Disorders
- 12.4.5. Others
- 12.5. Market Value Forecast, by End-user, 2017-2031
- 12.5.1. Hospitals
- 12.5.2. Clinics
- 12.5.3. Home Care
- 12.5.4. Ambulatory Care Settings
- 12.5.5. Others
- 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.6.1. Germany
- 12.6.2. U.K.
- 12.6.3. France
- 12.6.4. Italy
- 12.6.5. Spain
- 12.6.6. Rest of Europe
- 12.7. Market Attractiveness Analysis
- 12.7.1. By Product
- 12.7.2. By Drug Delivery Mode
- 12.7.3. By Therapeutic Area
- 12.7.4. By End-user
- 12.7.5. By Country/Sub-region
13. Asia Pacific Smart Drug Delivery Systems Market Analysis and Forecast
- 13.1. Introduction
- 13.2. Market Value Forecast, by Product, 2017-2031
- 13.2.1. Connected Inhalers
- 13.2.2. Connected Autoinjectors
- 13.2.3. Connected Pen Injectors
- 13.2.4. Connected Wearable Injectors
- 13.2.5. Add-on Sensors
- 13.2.6. Others
- 13.3. Market Value Forecast, by Drug Delivery Mode, 2017-2031
- 13.3.1. Injectable
- 13.3.2. Inhalation
- 13.3.3. Oral
- 13.4. Market Value Forecast, by Therapeutic Area, 2017-2031
- 13.4.1. Metabolic Disorders
- 13.4.2. Neurological Disorders
- 13.4.3. Respiratory Disorders
- 13.4.4. Hormonal Disorders
- 13.4.5. Others
- 13.5. Market Value Forecast, by End-user, 2017-2031
- 13.5.1. Hospitals
- 13.5.2. Clinics
- 13.5.3. Home Care
- 13.5.4. Ambulatory Care Settings
- 13.5.5. Others
- 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.6.1. China
- 13.6.2. Japan
- 13.6.3. India
- 13.6.4. Australia & New Zealand
- 13.6.5. Rest of Asia Pacific
- 13.7. Market Attractiveness Analysis
- 13.7.1. By Product
- 13.7.2. By Drug Delivery Mode
- 13.7.3. By Therapeutic Area
- 13.7.4. By End-user
- 13.7.5. By Country/Sub-region
14. Latin America Smart Drug Delivery Systems Market Analysis and Forecast
- 14.1. Introduction
- 14.2. Market Value Forecast, by Product, 2017-2031
- 14.2.1. Connected Inhalers
- 14.2.2. Connected Autoinjectors
- 14.2.3. Connected Pen Injectors
- 14.2.4. Connected Wearable Injectors
- 14.2.5. Add-on Sensors
- 14.2.6. Others
- 14.3. Market Value Forecast, by Drug Delivery Mode, 2017-2031
- 14.3.1. Injectable
- 14.3.2. Inhalation
- 14.3.3. Oral
- 14.4. Market Value Forecast, by Therapeutic Area, 2017-2031
- 14.4.1. Metabolic Disorders
- 14.4.2. Neurological Disorders
- 14.4.3. Respiratory Disorders
- 14.4.4. Hormonal Disorders
- 14.4.5. Others
- 14.5. Market Value Forecast, by End-user, 2017-2031
- 14.5.1. Hospitals
- 14.5.2. Clinics
- 14.5.3. Home Care
- 14.5.4. Ambulatory Care Settings
- 14.5.5. Others
- 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 14.6.1. Brazil
- 14.6.2. Mexico
- 14.6.3. Rest of Latin America
- 14.7. Market Attractiveness Analysis
- 14.7.1. By Product
- 14.7.2. By Drug Delivery Mode
- 14.7.3. By Therapeutic Area
- 14.7.4. By End-user
- 14.7.5. By Country/Sub-region
15. Middle East & Africa Smart Drug Delivery Systems Market Analysis and Forecast
- 15.1. Introduction
- 15.2. Market Value Forecast, by Product, 2017-2031
- 15.2.1. Connected Inhalers
- 15.2.2. Connected Autoinjectors
- 15.2.3. Connected Pen Injectors
- 15.2.4. Connected Wearable Injectors
- 15.2.5. Add-on Sensors
- 15.2.6. Others
- 15.3. Market Value Forecast, by Drug Delivery Mode, 2017-2031
- 15.3.1. Injectable
- 15.3.2. Inhalation
- 15.3.3. Oral
- 15.4. Market Value Forecast, by Therapeutic Area, 2017-2031
- 15.4.1. Metabolic Disorders
- 15.4.2. Neurological Disorders
- 15.4.3. Respiratory Disorders
- 15.4.4. Hormonal Disorders
- 15.4.5. Others
- 15.5. Market Value Forecast, by End-user, 2017-2031
- 15.5.1. Hospitals
- 15.5.2. Clinics
- 15.5.3. Home Care
- 15.5.4. Ambulatory Care Settings
- 15.5.5. Others
- 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 15.6.1. GCC Countries
- 15.6.2. South Africa
- 15.6.3. Rest of Middle East & Africa
- 15.7. Market Attractiveness Analysis
- 15.7.1. By Product
- 15.7.2. By Drug Delivery Mode
- 15.7.3. By Therapeutic Area
- 15.7.4. By End-user
- 15.7.5. By Country/Sub-region
16. Competition Landscape
- 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
- 16.2. Market Share Analysis, by Company (2021)
- 16.3. Company Profiles
- 16.3.1. Abbott Laboratories
- 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.1.2. Product Portfolio
- 16.3.1.3. Financial Overview
- 16.3.1.4. Strategic Overview
- 16.3.1.5. SWOT Analysis
- 16.3.2. Adherium Ltd.
- 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.2.2. Product Portfolio
- 16.3.2.3. Financial Overview
- 16.3.2.4. Strategic Overview
- 16.3.2.5. SWOT Analysis
- 16.3.3. Amiko Digital Health Limited
- 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.3.2. Product Portfolio
- 16.3.3.3. Financial Overview
- 16.3.3.4. Strategic Overview
- 16.3.3.5. SWOT Analysis
- 16.3.4. Becton, Dickinson and Company
- 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.4.2. Product Portfolio
- 16.3.4.3. Financial Overview
- 16.3.4.4. Strategic Overview
- 16.3.4.5. SWOT Analysis
- 16.3.5. BIOCORP
- 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.5.2. Product Portfolio
- 16.3.5.3. Financial Overview
- 16.3.5.4. Strategic Overview
- 16.3.5.5. SWOT Analysis
- 16.3.6. CeQur Corporation
- 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.6.2. Product Portfolio
- 16.3.6.3. Financial Overview
- 16.3.6.4. Strategic Overview
- 16.3.6.5. SWOT Analysis
- 16.3.7. Cognita Labs
- 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.7.2. Product Portfolio
- 16.3.7.3. Financial Overview
- 16.3.7.4. Strategic Overview
- 16.3.7.5. SWOT Analysis
- 16.3.8. E3D Elcam Drug Delivery Devices
- 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.8.2. Product Portfolio
- 16.3.8.3. Financial Overview
- 16.3.8.4. Strategic Overview
- 16.3.8.5. SWOT Analysis
- 16.3.9. H&T Presspart Manufacturing Ltd.
- 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.9.2. Product Portfolio
- 16.3.9.3. Financial Overview
- 16.3.9.4. Strategic Overview
- 16.3.9.5. SWOT Analysis
- 16.3.10. HCmed Innovations Co., Ltd.
- 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.10.2. Product Portfolio
- 16.3.10.3. Financial Overview
- 16.3.10.4. Strategic Overview
- 16.3.10.5. SWOT Analysis
- 16.3.11. Medtronic plc
- 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.11.2. Product Portfolio
- 16.3.11.3. Financial Overview
- 16.3.11.4. Strategic Overview
- 16.3.11.5. SWOT Analysis
- 16.3.12. Novo Nordisk
- 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.12.2. Product Portfolio
- 16.3.12.3. Financial Overview
- 16.3.12.4. Strategic Overview
- 16.3.12.5. SWOT Analysis
- 16.3.13. Phillips-Medisize
- 16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.13.2. Product Portfolio
- 16.3.13.3. Financial Overview
- 16.3.13.4. Strategic Overview
- 16.3.13.5. SWOT Analysis
- 16.3.14. Sonceboz
- 16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.14.2. Product Portfolio
- 16.3.14.3. Financial Overview
- 16.3.14.4. Strategic Overview
- 16.3.14.5. SWOT Analysis